NCT01298180已完成4 期
Is There a Sensibility Increased in the Growth Hormone at Child With Prader-Willi Syndrome?
适应症
干预措施
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 111
- 试验地点
- 26
- 主要终点
- Measure of the circulating rates of IGF-I under treatment.
研究概览
简要总结
The purpose of this study is to estimate the sensibility at the growth hormone in vivo at the children presenting a Prader-Willi syndrome (SPW) in comparison with children presenting a deficit in growth hormone (GHD).
详细描述
Estimate the sensibility at the growth hormone in vivo at the children presenting a Prader-Willi syndrome (SPW) in comparison with children presenting a deficit in growth hormone (GHD) by the measure of the circulating rates of IGF-I under treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 1 Year 至 5 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •SPW and SPW-B :
- •Female or male child of age > or = 1 year
- •Child naïve of treatment by GH and that must begin a treatment with GH
- •Child covered by a national insurance scheme or an equivalent
- •Signature of the informed consent by one of both holders of the parental authority
- •Female or male child of age > or = 1 year
- •Child paired for the age (+/-on 1 year) and for the sex with regard to the group SWP
- •Child presenting a GH* deficiency defined by :
- •Growth criteria of size (size) < 2 DS) Criteria of speed of growth (speed of growth < 1 DS over the last year) 2 tests of pharmacological stimulation of GH with peak GH max < 20 mUI
- •Child naïve of treatment by GH and that must begin a treatment with GH
- •Child covered by a national insurance scheme or an equivalent
- •Signature of the informed consent by one of both holders of the parental authority * The deficit in GH can be isolated or associated with one or several other hormonal deficits: deficit in TSH, deficit in ACTH, deficit in LH-FSH, deficit in prolactin. The child GHD can thus receive other treatments associated with the growth hormone.
- •T : controls
- •Female or male child of age > or = 1 year
- •Child paired for the age (+/-on 1 year) and for the sex with regard to the group SWP
- •Child hospitalized at the hospital of the children of the University Hospital of Toulouse for a programmed surgical operation
- •Child covered by a national insurance scheme or an equivalent
- •Signature of the informed consent by one of both holders of the parental authority
- •Female or male child of age > or = 1 year
- •Child hospitalized for a programmed surgical operation
- •Child covered by a national insurance scheme or an equivalent
- •Child treated with GH for at least 3 month
- •Signature of the informed consent by one of both holders of the parental authority
排除标准
- •SPW and GHD
- •Child presenting a contraindication to the taking of growth hormone :
- •Growth cartilage welded
- •Tumoral pathology in process of evolution
- •Corticosteroid therapy (not substitute)
- •Allergy known about solvent
- •Badly balanced diabetes
- •Child presenting a hypersensitivity to the active principle or to one of the excipients of Genotonorm ® or Omnitrope ®
- •Child presenting a severe obesity (defined by a report weight / size > 200 %)
- •Child presenting clinical signs ENT (snores associated with a hypertrophy of the adenoids vegetations and\or the tonsils)
- •Child presenting clinical signs evoking a respiratory illness of the sleep (night-respiratory snores, respiratory breaks during the sleep)
- •Child presenting a hypersensitivity to the local anaesthetic with amide connecion
- •Child presenting a hypersensitivity to the components of the bandage Emlapatch®
- •Child presenting a hypersensitivity to one of the components of the lidocaïne aguettant without conservative®
- •Child presenting a porphyria
- •Child presenting a congenital methemoglobinemia
- •Child presenting a contraindication to Meopa : patients requiring a ventilation in pure oxygen, intracranial High blood pressure, Any change of the state of consciousness, preventing the cooperation of the patient, Pneumothorax, Bubbles of emphysema, Gaseous embolism, Accident of dive, abdominal gaseous Distension, Patient having received recently an ophthalmic gas (SF6, C3F8, C2F6) used in the eye surgery as long as persists a bubble of gas inside the eye and at least during a period of 3 months. Grave postoperative complications can arise in touch with the increase of the pressure intraocular, facial Traumatism interesting the region of application of the mask
- •T : controls
- •Chronicle pathology in which an abnormality of growth would be involved
- •Other hormonal abnormalities
- •Children receiving a treatment on the long range, corticosteroid therapy in particular, being able to interfere with the sensibility to GH or to the insulin
- •Holder of the parental authority under supervision, guardianship or under protection of justice
- •Participation in another study simultaneously at this one
研究组 & 干预措施
SPW
Experimental
Children presenting a Prader-Willi Syndrome
干预措施: Growth hormone (Genotonorm® or Omnitrope®) (Drug)
SPW
Experimental
Children presenting a Prader-Willi Syndrome
干预措施: DEXA, blood tests, H.G.P.O, osseous age. (Procedure)
GHD
Experimental
Patient deficient in Growth Hormone
干预措施: Growth hormone (Genotonorm® or Omnitrope®) (Drug)
GHD
Experimental
Patient deficient in Growth Hormone
干预措施: DEXA, blood tests, H.G.P.O, osseous age. (Procedure)
SPW-B
Experimental
Patient with Prader-Willi Syndrome who has Biopsy
干预措施: Growth hormone (Genotonorm® or Omnitrope®) (Drug)
SPW-B
Experimental
Patient with Prader-Willi Syndrome who has Biopsy
干预措施: DEXA, blood tests, H.G.P.O, osseous age. (Procedure)
SPW-B
Experimental
Patient with Prader-Willi Syndrome who has Biopsy
干预措施: biopsy (Procedure)
T
Experimental
Patient Control
干预措施: biopsy (Procedure)
SPW-GH-B
Experimental
Patient with Prader-Willi Syndrome taking growth Hormone and who has biopsy
干预措施: biopsy (Procedure)
结局指标
主要结局
Measure of the circulating rates of IGF-I under treatment.
时间窗: 1 year (M12)
次要结局
- Measure of blood sugar level, H.G.P.O., and hyperglycaemia.(1 year (M12))
- Measure of the circulating rate of IGFBP-3, GHBP, ghrelin and apelin.(1 year (M12))
- Measure of physical composition's variation.(1 year (M12))
- Measure of the sensibility at the growth hormone in vitro, on fibroblasts and adipocytes obtained by biopsy.(1 year (M12))
研究者
研究点 (26)
Loading locations...
相似试验
已完成
1 期
Effects of Growth Hormone on the Nitric Oxide PathwayCardiovascular DiseaseNCT00470002Hannover Medical School16
进行中（未招募）
不适用
A study to determine the effects of growth hormone (GH) replacement therapy on quality of life and cardiovascualr risk in GH deficient adults - Growth Hormone and Quality of Life (GroH-QoL)EUCTR2004-004835-72-GBniversity of Birmingham200
已完成
不适用
Effect of Growth Hormone on Insulin Signaling in Muscle TissueInsulin ResistanceNCT00477997University of Aarhus8
已完成
2 期
Individualizing Dose of Growth Hormone to Maintain Normal Growth Velocity After Fulfilled Catch up Growth in ChildrenShort StatureNCT02879747Göteborg University99
已完成
3 期
The Effect of Growth Hormone in Very Young Girls With Turner SyndromeTurner SyndromeNCT00406926Eli Lilly and Company100